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Early intervention in patients at ultra high
risk of psychosis: beneﬁts and risks
de Koning MB, Bloemen OJN, van Amelsvoort TAMJ, Becker HE,
Nieman DH, van der Gaag M, Linszen DH. Early intervention in
patients at ultra high risk of psychosis: beneﬁts and risks.
Objective: Prediction of transition to psychosis in the prodromal phase
of schizophrenia has raised interest in intervention prior to the onset of
frank psychosis. The aim of this review was to examine whether
interventions in the prodromal phase have a favourable beneﬁt ⁄ risk
ratio.
Method: A literature search in PubMed, EMBASE and PsycINFO was
performed.
Results: Three randomized clinical trials with antipsychotic medication
and ⁄or cognitive behavioural therapy as clinical intervention suggested
a positive eﬀect at the end of treatment, but no signiﬁcant diﬀerences
were found at the end of follow-up periods from 1 to 4 years.
Naturalistic studies present a hypothesis about a possible preventive
eﬀect of antidepressive medication. The results of eight other studies are
more diﬃcult to interpret. Side-eﬀects of antipsychotic medication and
non-adherence with medication are essential problems.
Conclusion: At the present time, the data concerning the beneﬁts and
risks do not justify prodromal intervention as standard clinical practice.
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Clinical recommendations
• Several treatments have been proposed for patients who are at ultra high risk (UHR) of developing a
psychosis: different types of medication (antipsychotics: olanzapine, risperidone, aripiprazol,
amisulpride, haloperidol; Selective Serotonin Reuptake Inhibitors; omega-3 fatty acids; glycine);
CBT; skills training; psychoeducation and family interventions. Treatments are aimed at reducing the
risk of transition to psychosis and ⁄or treatment of the actual symptoms.
• A deﬁnitive conclusion about the efﬁcacy and safety of all these interventions cannot be drawn at this
moment.
• UHR patients should be monitored regularly and actively and deﬁned comorbid syndromes such as
depression and substance-use disorders should be dealt with adequately.
• A possible strategy when treating an UHR patient is providing extensive information about the
possible beneﬁt and risks of the different interventions and providing treatment based on the
preferences of each individual patient.
Additional comments
• Only a few randomized trials have been published, but pharmacological interventions and CBT have
shown encouraging results that justify further research.
• Prediction algorithms might be improved, thus lowering the number of false positives. With
improved prediction algorithms, the validity of efﬁcacious and effective interventions might increase,
and analysis of beneﬁts and risks might be more favourable.
• Even with better prediction algorithms, the emphasis of the UHR criteria will be on attenuated
psychotic symptoms and brief limited psychosis. Neurocognitive dysfunctioning and negative
symptoms are core features of schizophrenia and of the UHR state which are until now far more
difﬁcult to inﬂuence.
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Introduction
Schizophrenia is a serious illness that usually
manifests itself in adolescence or early adulthood.
It has a potentially chronic course and the outcome
is often poor. Over the last two decades, interest has
grown in the potential beneﬁts of interventionbefore
the onset of psychosis. In this paper, the literature on
interventions in the phase preceding the ﬁrst
psychosis will be reviewed, but ﬁrst relevant
conceptsandpreceding issueswill be shortly addressed.
Preventive interventions: definitions
Throughout medicine, the last decades have shown
a movement towards prevention.
In 1994, Mrazek and Haggerty (1) described the
diﬃculties with the traditional public health
classiﬁcation system of primary, secondary and
tertiary prevention, which makes the classiﬁcation
system less useful for prevention of mental health
disorders. They questioned the use of the term
prevention for situations in which a disorder is
already present, as in tertiary prevention.
Furthermore, they pointed at the unclear deﬁnition
of secondary prevention. The term secondary
prevention is used in two diﬀerent ways: i) early
detection of a disease and preventing progression
of the disease and ii) detection of prodromal
symptoms of a disease and preventing full mani-
festation of the disease.
To overcome these diﬃculties, they described a
mental health intervention spectrum, in which the
term prevention is reserved for interventions that
take place when there is (still) no clinically diag-
nosable disorder. Then, the aim of prevention was
to reduce the occurrence of new cases of a clinically
diagnosable disorder (2).Prevention is divided
into three subcategories: universal prevention,
selective prevention and indicated prevention (1).
Universal prevention is prevention in the whole
population, selective prevention is prevention in a
subgroup with risk factors but without any
symptoms and indicated prevention is prevention
in a group of persons with minimal but detectable
symptoms but no clinically diagnosable disorder.
As the risk of developing a disorder increases
along these three subgroups, the criteria for
economically and ethically justiﬁed interventions
get less strict. Universal prevention is acceptable
when costs are low, the intervention is eﬀective and
the risk of adverse eﬀects is low. Indicated preven-
tion may be reasonable even at high costs and when
there is some risk of adverse eﬀects, especially if a
serious disorder is implied and if the incidence of the
disorder in the targeted subgroup is high (1, 2).
Universal and selective prevention are only
possible when the aetiology of a disease is
known, and when aetiological risk factors can be
eliminated. In the case of psychosis, many risk
factors are known, but each makes a small contri-
bution to the total risk, and they are hard to
inﬂuence. Eﬀective universal and selective preven-
tion strategies are, until now, not available (3, 4).
In this paper, studies on indicated preventive
interventions will be reviewed.
The putatively prodromal state: operationalization criteria
In the phase preceding a ﬁrst psychotic episode,
many symptoms may be present: depressed mood,
anxiety, irritability, changes in volition, cognitive
changes (e.g. thought blocking), physical symptoms
(e.g. sleep disturbances), behavioural changes (e.g.
social withdrawal), impaired tolerance to normal
stress and attenuated psychotic symptoms (5–7).
Many of these symptoms are not speciﬁc for the
psychotic prodrome and might also be the ﬁrst
manifestation of another disorder, for example a
major depression (8). Attenuated psychotic symp-
toms occur late in the disease process (6).
As prodromal is a retrospective concept (5), a
patient with prodromal symptoms actually has
putatively prodromal symptoms (9). Criteria had
to be developed to operationalize this putatively
prodromal state. Diﬀerent research groups have
developed diﬀerent early detection instruments
and operationalization criteria, which will be
discussed below. All diﬀerent names used for the
putatively prodromal state [e.g. ultra high risk
state (UHR), at-risk mental state (ARMS), early
initial prodromal state (EIPS) and clinical high
risk state (CHR)] have their own deﬁnition,
which are sometimes much alike, but almost
never identical. The most widely used name is
UHR: UHR patients and UHR state. Although
this name originally referred to a speciﬁc set of
operationalization criteria, nowadays it is often
used to refer to the whole group of patients with
putatively prodromal symptoms. Therefore, in
this review, the name UHR has been used,
when referring to putatively prodromal symptoms
or patients with these symptoms. For each
described study, the speciﬁc operationalization
criteria of the UHR state in that study have been
mentioned.
The UHR approach. In 1994, the Personal Assess-
ment and Crisis Evaluation (PACE) Clinic in
Melbourne (Australia) started to develop the
UHR approach. The researchers described a set
of criteria, combining risk factors (age and family
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history) with clinical symptoms. The symptom
scores are based on subjective information from
the patient and on observation by the rater.
Individuals meeting a deﬁned combination of risk
factors are at UHR of developing a psychosis (5),
indicating an increased risk for developing a ﬁrst
psychotic episode within a year.
Yung and McGorry (6) described the current
UHR criteria as follows [for more details see Yung
et al. (10, 11)]:
The current UHR criteria require that a help
seeking young person be aged between 14 and
29 years, is referred to a clinical service and meets
criteria for one or more of the following groups:
i) Attenuated psychotic symptoms group (APS):
have experienced sub-threshold, attenuated
psychotic symptoms during the past year;
ii) Brief limited intermittent psychotic symptoms
group (BLIPS): have experienced episodes of
frank psychotic symptoms that have not lasted
longer than a week and have been spontane-
ously abated;
iii) State and trait risk factor group: have schizo-
typal personality disorder or a ﬁrst-degree
relative with a psychotic disorder, and have
experienced a signiﬁcant decrease in function-
ing during the previous year.
The PACE research team developed the ﬁrst early
assessment instrument Comprehensive Assessment
of At-Risk Mental States (CAARMS) in 1996 and
reﬁned it in the next 9 years (12). The CAARMS is a
structured diagnostic interview on positive and
negative symptoms, and other symptoms (e.g.
cognitive changes, behavioural changes, emotional
disturbances) that can occur in the prodromal state.
The criteria for being at UHR were precisely
deﬁned, and consisted of thresholds for intensity,
frequency and duration of the positive symptoms
(for APS and BLIPS) and a precise deﬁnition of
signiﬁcant decrease in functioning (for the state and
trait risk factor group). Criteria for experiencing a
psychotic episode (at present or in the past) were
precisely deﬁned as well and are based on intensity,
frequency and duration of positive symptoms.
Patients fulﬁlling the prodromal criteria in the
CAARMS have been named UHR patients, but
also ARMS patients or patients fulﬁlling PACE
criteria.
Shortly after the development of the ﬁrst version
of the CAARMS in 1996, the Prevention through
Risk Identiﬁcation, Management, and Education
(PRIME) prodromal research team at Yale Uni-
versity (USA) developed the Structured Interview
for Prodromal Syndromes (SIPS), including the
scoring list Scale of Prodromal Symptoms (SOPS)
(13). The instrument was further developed in the
next years (14). The SIPS and SOPS were based on
the UHR approach developed in the PACE Clinic
by Yung et al. (5). As in the CAARMS, the
SIPS includes precisely deﬁned criteria for the
UHR state (the Criteria of Prodromal Syndromes,
COPS) and for the psychosis-threshold (Presence
of Psychotic Syndrome, POPS) (14). Patients
fulﬁlling the prodromal criteria in the COPS have
been named UHR patients, The structured inter-
views of the SIPS and the CAARMS have
converged over the times, as have the UHR and
psychosis criteria. Subtle diﬀerences are mainly
found in frequency and duration criteria.
The UHR criteria (COPS or CAARMS) have
been used by several research clinics besides the
PACE clinic and the PRIME clinic (e.g. the Early
Identiﬁcation and Intervention Evaluation Clinic
in Manchester, UK), sometimes with slight
modiﬁcations. The 12-month transition rate to
psychosis varies between 9 and 54% [for a
summary see Haroun et al. (15)].
The basic symptom approach. Another early detec-
tion instrument was developed in Germany, and it
originated from a diﬀerent approach. Departing
from the fundamental symptoms of schizophrenia
as hypothesized by the Swiss psychiatrist Bleuler,
the concept of basic symptomswas developed by the
German psychiatrists Gross and Huber. The basic
symptoms are subjectively experienced well-deﬁned
symptoms, amongst others cognitive symptoms,
that were thought to be core signs of schizophrenia.
They were translated to the Bonn Scale for the
assessment of Basic Symptoms (BSABS) (16).
Klosterkotter et al. (7) studied the predictive
capacity of basic symptoms with a shortened
66-item version of the BSABS in a group of 160
patients who were not psychotic but were referred
by their clinician as being at risk for developing
schizophrenia. During a follow-up period of
9.6 years, 79 of the 160 patients developed schizo-
phrenia. The presence of at least one basic symp-
tom at baseline had a positive predictive value of
0.70, and the absence of basic symptoms had a
negative predictive value of 0.96. From the 66
BSABS items, 10 items fulﬁlled the criteria of
sensitivity >0.25 and a positive predictive value of
>0.70, that were deﬁned on forehand (e.g. thought
interference, thought blockages and acoustic
perception disturbances).
Based on this study, the authors developed a new
instrument, the BSABS – Prediction List (17), a list
of nine symptoms, with a cut-oﬀ score for being at
high risk of developing schizophrenia when two or
more of these symptoms are present. The predictive
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validity of this instrument is currently being
examined in the European Prediction of Psychosis
Study (18). Because the basic symptoms refer to
subtle subjectively experienced abnormalities, they
may refer to an earlier phase in the disease process
than the UHR criteria in the CAARMS and the
COPS.
Potential benefits of prepsychotic intervention
There are, at least, three possible mechanisms for
improving the course of the disease by intervention
before onset of psychosis. First, it might be
possible to prevent psychosis by intervening in a
crucial phase of beginning symptoms.
Second, it might be possible to improve the
course of the disease by improving the mental state
in the prodromal phase or by postponing the ﬁrst
psychotic episode. It has been hypothesized that
much harm is done already in the prodromal
phase. This hypothesis refers to possible loss of
grey matter at the time of transition to psychosis
(19) and to functional decline (20). The major
source of disability in schizophrenia is decline in
social and work skills. By improving these skills in
the prodromal phase and ⁄or by giving a patient
more healthy years in the crucial adolescent phase
of building relationships and studying, functional
decline might be limited (21).
Finally, the ﬁrst psychotic episode might have a
more favourable course after intervention in the
prodromal phase, because the patient is already
enrolled in a mental health treatment program: a
psychosis will be discovered soon after onset, and
the patient might be more willing to accept
treatment, thus shortening the duration of
untreated psychosis (22, 23).
Potential risks of prepsychotic intervention
Risks of intervention primarily concern two issues:
drug side-eﬀects and stigma or anxiety because of
the word psychosis being used. Both risks are
especially important because of the false-positive
UHR subjects who will not develop a psychosis. In
intervention studies, it is impossible to know the
number of false-positive subjects, because theremay
be false false positives: subjects that do not make
the transition to psychosis, but who would have if
they had not been treated (10). False positives and
false false positives cannot be distinguished at
follow-up, so it is impossible to know how many
subjects have been treated unnecessarily.
The potential risk of stigmatizing has often been
discussed. One should keep in mind, however, that
UHR subjects are subjects who have psychological
or psychiatric problems. They are help-seeking,
often low-functioning individuals. In practice,
researchers have found that good education
about psychosis and about the risk and uncertainty
of transition, is often accepted and does not seem
to be stigmatizing (24).
Earlier reviews on intervention studies in UHR subjects
The most recent reviews on this topic that were
found, date from 2006: a Cochrane review (data-
base search until March 2006) (25) and a compre-
hensive review article on prospective investigations
of the prodromal state of schizophrenia by Olsen
and Rosenbaum (database search until August
2005) (26).
Since then,many new results have been published,
which justiﬁes a new review. Furthermore, in the
Cochrane review only three randomized controlled
trials were included. The results of the Cochrane
review were inconclusive. In the present review all
available information will be included, because in
clinical practice the need for knowledge about
interventions in UHR subjects is high.
Olsen and Rosenbaum gave a complete overview
of prospective studies until August 2005, focusing
on operationalization criteria of the putatively
prodromal state, and prediction of transition to
psychosis in naturalistic studies, as well as on
eﬀects of interventions. They paid much attention
to conceptual and methodological issues in the
ﬁeld. In contrast, the present review aims to
examine whether interventions in UHR subjects
have a favourable beneﬁt ⁄ risk ratio, by giving a
clinical overview that focuses on eﬀects of inter-
ventions only, and especially on the meaning of
research results for clinical practice.
Aims of the study
The aim of this paper was to review all inter-
ventions in UHR subjects through a literature
search. The main question is whether beneﬁts of
intervention during this phase outweigh the risks
associated with intervention.
Material and methods
We searched PubMed, EMBASE and PsycINFO
databases from January 1980 to June 2008, using
the keywords (early intervention OR prevent*)
AND (psychosis) AND (ultra high risk OR
prodrom*). Only publications in English or with
at least an abstract available in English were
included. The reference lists of retrieved articles
were searched for additional articles. If a retrieved
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article was part of a special theme issue on the
subject, the whole issue was screened. Abstract
books of conferences on the subject were screened
from January 2005 to June 2008.
In line with the aim of this paper, we searched
for studies that gave information about the eﬃcacy
of interventions in UHR subjects. We did not
include: studies assessing the feasibility or tolera-
bility of interventions or the feasibility of running a
clinical service for UHR subjects, naturalistic
studies describing the percentage of transition to
psychosis and the prediction of psychosis, descrip-
tions of UHR subjects at the point of inclusion in a
study, and validation studies on operationalization
criteria or early detection instruments. Neither did
we include unpublished studies in progress,
Inclusion of studies: design and quality
Because of the limited number of randomized
clinical trials, studies with other methodological
designs will also be reviewed. We included
intervention studies without a control group,
because these studies are often the ﬁrst indication
of a possible positive eﬀect of an intervention and
can prompt further research. We also included
naturalistic studies in which the eﬀects of diﬀerent
non-experimental interventions are compared
retrospectively. Although this kind of design
leads to a bias, it may generate interesting hypo-
theses. Finally, we included results presented in
abstracts, which can provide important additional
information, when there are so few trials with
results published in full articles.
Inclusion of studies: intervention
Diﬀerent research groups have used – or evaluated,
in the case of naturalistic, retrospective studies –
several diﬀerent interventions, sometimes in com-
bination: diﬀerent types of medication [antipsy-
chotics: olanzapine, risperidon, aripiprazol,
amisulpride, haloperidol; Selective Serotonin
Reuptake Inhibitors; omega-3 fatty acids; glycine);
diﬀerent types of CBT; skills training; psychoedu-
cation and family interventions. Therefore, it is
diﬃcult to compare the diﬀerent studies. Because
of the novelty of the ﬁeld and the impossibility to
decide on forehand which interventions are the
most promising, every study will be reviewed,
irrespective of the type of intervention used.
Inclusion of studies: outcome measures
Two main outcome measures can be discerned:
the percentage of transition to psychosis vs. acute
treatment eﬀects in the present phase. They will
both be addressed in this review, because in
clinical practice both outcome measures are
important.
Results
With the search in PubMed, EMBASE and
PsycINFO, 56 articles could be retrieved that
considered the subject. Of these 56 articles, 12
articles described the eﬀect of an intervention. The
other 44 articles were descriptions of study designs,
descriptions of interventions and clinical settings,
reviews, commentaries and case reports. By search-
ing the reference lists of retrieved articles, special
theme issues and abstract books, eight addi-
tional articles ⁄abstracts could be retrieved that
described the eﬀect of an intervention. Three
articles ⁄abstracts described the same results; the
most recent and complete description was selected.
Thus, a total number of 18 articles ⁄abstracts were
found.
Studies focusing on the prevention of transi-
tion to psychosis are reviewed ﬁrstly and are
listed in Table 1. Randomized controlled trials,
trials without control intervention and naturalis-
tic studies with retrospective comparisons of
interventions are reviewed separately. Studies
focusing on acute treatment eﬀects are reviewed
in secondly and are listed in Table 2.
Prevention of transition to psychosis
The ﬁrst study, to our knowledge, that focused on
detection of possible prodromal symptoms was
conducted by Falloon et al. (27). In an area of
35 000 inhabitants, they oﬀered education, stress
management techniques and low-dose antipsy-
chotic medication to patients with possible
prodromal symptoms (deﬁned by DSM-III-pro-
dromal symptoms and ten additional symptoms).
The authors found a ten-fold reduction of the
incidence of schizophrenia within the area, com-
pared with a previous period. The study has
multiple methodological limitations, of which the
most important is the uncertain comparability with
the historical control group (28). However, the
results of this innovative and provocative study
have inspired many researchers in the ﬁeld of
prepsychotic intervention.
Randomized controlled trials. Until June 2008, ﬁve
research groups have reported results from
randomized controlled trials evaluating the eﬃ-
cacy of diﬀerent treatment approaches in reduc-
ing the transition rate from UHR symptoms to
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psychosis. Deﬁnitive results have been published
for three of the ﬁve trials (9, 23, 29); for two of
these, long-term follow-up results have also been
published (30, 31). Results of the fourth and ﬁfth
trial have only been presented orally and in
abstracts (32–35).
Table 1. Studies on prevention of transition to psychosis
Study Inclusion criteria
Specific
intervention (SI)
Control
intervention (CI)
Primary outcome measure: transition to psychosis
Follow-up
< 1 year Follow-up 1 year Follow-up > 1 year
PACE (23, 30) UHR criteria (CAARMS)
(n = 59)
Risperidone
1–2 mg + CBT
(n = 31)
6 months
Needs-based
intervention
(n = 28)
6 months
After 6 months:
SI: 3 ⁄ 31 (10%)
CI: 10 ⁄ 28 (36%)
P = 0.03
After 12 months:
SI: 6 ⁄ 31 (19%)
CI: 10 ⁄ 28 (36%)
NS
After 3–4 years:
SI: 10 ⁄ 31 (32%)
CI: 12 ⁄ 28 (43%)
NS
PRIME (9) UHR criteria (COPS) (n = 60) Olanzapine 5–15 mg
(n = 31)
12 months
Placebo (n = 29)
12 months
After 12 months:
SI: 5 ⁄ 31 (16%)
CI: 11 ⁄ 29 (38%)
NS
EDIE (29, 31) UHR criteria (adaptation of
PACE criteria based on
PANSS) (n = 60)
2 patients excluded from
analysis
CT (n = 35)
6 months
Monitoring
(n = 23)
6 months
After 12 months:
SI: 2 ⁄ 35 (6%)
CI: 5 ⁄ 23 (22%)
P = 0.028
NB: NS if 2 excluded
patients are included
After 3 years:
Defined by PANSS:
SI: 7 ⁄ 35 (20%)
CI: 5 ⁄ 23 (22%)
NS
Defined by AP medi-
cation:
SI: 5 ⁄ 35 (14%)
CI: 8 ⁄ 23 (35%)
P = 0.024
GNRS EIPS
(32, 33)
= at least 1 basic symptom out
of 10 basic symptoms with
high predictive value, and ⁄ or
state and trait risk factor
(n = 128)
Comprehensive cog-
nitive behavioural
treatment (individual
cognitive therapy,
group intervention,
cognitive remedia-
tion, psychoeduca-
tional family
intervention) (n = ?)
12 months
Supportive coun-
selling (n = ?)
12 months
After 12 months:
Transition to LIPS:
SI: ? ⁄ ? (3.2%)
CI: ? ⁄ ? (16.9%)
P = 0.008
Transition to psychosis:
SI: ? ⁄ ? (1.6%)
CI: ? ⁄ ? (13.8%)
P = 0.020
After 24 months:
Transition to LIPS:
SI: ? ⁄ ? (6.3%)
CI: ? ⁄ ? (20.0%)
P = 0.019
Vienna, Austria
(34, 35 )
UHR criteria (n = 81)
(CAARMS)
Omega-3 fatty acids
1.5 g ⁄ day (n = 41)
12 weeks
Placebo (n = 40)
12 weeks
After 12 weeks:
SI: 1 ⁄ 38 (2.6%)
CI: 8 ⁄ 38 (21.2%)
P = 0.028 (5 pa-
tients excluded
from analysis for
unclear reason)
After 12 months:
SI: 2 ⁄ 41 (4.9%)
CI: 11 ⁄ 40 (27.5%)
P = 0.006
OPUS (36) Schizotypal disorder (n = 79) Integrated treatment
(ACT with family
intervention and so-
cial skills training)
(n = 42)
2 years
Standard treat-
ment (n = 37)
2 years
After 12 months:
SI: 3 ⁄ 37 (8.1%)
CI: 10 ⁄ 30 (25.0%)
NB: 12 patients lost to follow-
up not included in analysis
After 24 months:
SI: 9 ⁄ 36 (25.0%)
CI: 14 ⁄ 29 (48.3%)
P = 0.02
NB: 14 patients lost
to follow-up not in-
cluded in analysis
Szeged,
Hungary (45)
UHR criteria (n = 52)
(CAARMS)
Low-dose haloperidol
or risperidone 0.5–
2.0 mg ⁄ day (n = 52)
6 months
None After 6 months:
SI: 3 ⁄ 42 (7.1%)
NB: 10 patients
dropped-out
After 12 months:
SI: 3 ⁄ 42 (7.1%)
RAP (49) Retrospective design: attenu-
ated psychotic symp-
toms + pharmacological
treatment = 8 weeks + fol-
low-up at least 6 months
(n = 48)
Naturalistic design:
28 received AP med-
ication, often with
comedication (e.g.
AD)
20 received an AD,
but no antipsychotics
After maximum of 5 years:
AP medication: 12 ⁄ 28 (43%)
AD medication: 0 ⁄ 20 (0%)
P = 0.007
OASIS (50) Retrospective design: UHR
criteria (CAARMS) + pharma-
cological treatment with AD or
AP + follow-up 2 years
(n = 48)
Naturalistic design:
35 received AP med-
ication
13 received AD med-
ication
After 2 years:
AP medication: 10 ⁄ 35 (29%)
AD medication: 1 ⁄ 13 (8%)
No statistical analysis
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A sixth randomized controlled trial evaluated
the eﬃcacy of an intervention in reducing the
transition rate from schizotypal disorder to
psychosis (36). This is a diﬀerent patient group,
but we included the study because of the partial
overlap between UHR criteria and criteria for
schizotypal disorder.
The PACE clinic study (Australia). The ﬁrst
randomized trial compared the outcome in two
groups of UHR participants, selected with the
PACE criteria, which were later elaborated in the
CAARMS: a group who received a combination of
1–2 mg risperidone plus CBT (speciﬁc intervention:
SI, n = 31) and a group who received supportive
psychotherapy only (needs-based intervention:
NBI, n = 28) (23). The main outcome measure
was transition to psychosis, operationally deﬁned
using threshold scores on the Brief Psychiatric
Rating Scale (37) and the Comprehensive Assess-
ment of Symptoms and History (38). Study
participants and clinicians were not blind to
treatment; research interviewers intended to be
blind, but this proved to be diﬃcult. Treatment
was provided for 6 months with follow-up
6 months later. Follow-up in these 12 months
was 100%.
When analysed by intention-to-treat, signiﬁ-
cantly more people in the NBI group had
developed a psychotic episode by the end of the
treatment phase than in the SI group
(10 ⁄28 = 36% vs. 3 ⁄31 = 10%). This diﬀerence
was no longer signiﬁcant at the follow-up at
12 months because of the progression to psychosis
of three more SI participants between months 6
and 12.
Levels of all symptoms improved in both groups.
There was no diﬀerence in symptom improvement
between the NBI and the SI group. Levels of
functioning remained stable in both groups.
Neuroleptic adverse eﬀects were present in four
patients and were relieved by dose reduction.
Follow-up interviews took place 3–4 years after
study entry (30). Follow-up was 24 ⁄31 (77%) in the
SI group and 17 ⁄28 (61%) in the NBI group.
Between the 12-month and the 3–4-year follow-
ups, two people from the NBI group and four
people from the SI group developed psychosis.
There was no signiﬁcant diﬀerence in the prob-
ability of developing psychosis between the NBI
and the SI group over the entire duration of the
study. Neither were there any diﬀerences in symp-
tomatology or functioning between the groups.
The PRIME study (USA). The PRIME study is a
randomized double-blind placebo-controlled trial
which compared the outcome of UHR participants
who received olanzapine 5–15 mg (n = 31) with
participants who received placebo (n = 29) (24).
The UHR state was deﬁned by COPS criteria. The
main outcome measure was transition to psychosis,
operationally deﬁned by the POPS (39). Treatment
was provided for 1 year, with a further 1-year
follow-up.
Participation at follow-up was low: 14 ⁄31 (45%)
in the olanzapine group and 19 ⁄29 (66%) in the
placebo group; the diﬀerence in drop-out rate was
not signiﬁcant. All drop-out took place in the ﬁrst
year.
In the olanzapine group, 5 ⁄31 participants
became psychotic during the intervention (16%)
and three more during the follow-up year (total
8 ⁄31 = 26%). In the placebo group, 11 ⁄29
participants became psychotic during the treatment
year (38%) and two more during the follow-up year
(total 13 ⁄29 = 45%). Although the rate of con-
version to psychosis seemed higher in the placebo
group during the ﬁrst year, this diﬀerence was not
signiﬁcant. This may be due to a lack of power.
Neither were there any signiﬁcant diﬀerences
between the two groups in changes in symptom
and functioning scores, although after the treat-
ment year the olanzapine group showed a greater
improvement in positive symptoms than the
placebo group, tending to signiﬁcance. When anal-
ysed with a mixed-eﬀects model repeated-measures
analysis, signiﬁcant between-treatment diﬀerences
were observed between weeks 8 and 28, when the
reductions in positive symptom scores were signif-
icantly greater for the olanzapine patients.
At follow-up, positive symptom scores worsened
signiﬁcantly in the former olanzapine group.
During the treatment year, fatigue was reported
by 29% of patients in the olanzapine group and
3% of patients in the placebo group; this diﬀerence
was signiﬁcant. The diﬀerence in weight gain was
also signiﬁcant: 8.8 kg in the olanzapine group vs.
0.3 kg in the placebo group.
The Early Detection and Intervention Evaluation study
(EDIE) (UK). This randomized trial compared
the outcome in two groups of UHR participants.
UHR was operationally deﬁned using an adapta-
tion of the PACE criteria, based on the Positive
and Negative Syndrome Scale (PANSS) (40). The
treatment group received cognitive therapy (CT)
(n = 37) and the control group received only
monitoring (n = 23) (29). The main outcome
measure was transition to psychosis, operationally
deﬁned based on the PACE criteria and the
PANSS, and ⁄or prescription of antipsychotic
medication, and ⁄or a DSM-IV diagnosis.
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Participants and clinicians could not be blinded
because of the nature of the intervention. Research
interviewers intended to be blind, but this proved
to be impossible. Treatment was provided for
6 months with follow-up 6 months later. Two of
the 37 participants in the CT group were excluded
from analysis because at the ﬁrst postrandomiza-
tion assessment, they both reported having had
concealed psychotic symptoms at baseline.
In the CT group, 26 ⁄35 (74%) completed CT
and follow-up. In the monitoring group, 16 ⁄23
(70%) completed follow-up.
The authors reported a signiﬁcant diﬀerence
between the CT and monitoring group in percent-
age of transition to psychosis at follow-up at
12 months [2 ⁄35 (6%) and 5 ⁄23 (22%) respec-
tively], suggesting that CT signiﬁcantly reduced the
likelihood of developing psychosis.
However, the omission of two participants from
analysis because of having been psychotic at the
time of randomization, is questionable, and might
not be compatible with true intention to treat
analysis. When included in the analysis and
counted as transitions to psychosis, the transition
rate in the CT group is 4 ⁄37 (11%) and the
diﬀerence is no longer signiﬁcant (25).
Positive symptoms diminished in both groups
during the 12-month trial, signiﬁcantly more in the
CT group than in the monitoring group. There
were no diﬀerences in levels of functioning between
the groups.
Follow-up interviews took place 3 years after
study entry (30). Follow-up rates were quite low:
17 ⁄35 (49%) in the CBT group and 10 ⁄23 (43%) in
the monitoring group.
Between the 12-month and the 3 year follow-up
period, there were ﬁve more transitions to psycho-
sis in the CT group and none in the monitoring
group, when transition was deﬁned by PACE ⁄ -
PANSS and DSM-IV criteria. There was no
signiﬁcant diﬀerence anymore between the two
groups in transition rate. However, when deﬁning
transition by being prescribed antipsychotic med-
ication, there was a signiﬁcant diﬀerence with a
lower percentage of transitions in the CT group.
These ﬁndings are diﬃcult to interpret because of
the diﬀerent methods used for deﬁning transition.
Prescription of antipsychotic medication might be
considered to be the most objective measure of
transition because it does not rely upon self-report
data from interviews. On the other hand, anti-
psychotic medication is increasingly used in
clinical practice for other disorders or UHR
symptoms (41).
At the 3 year follow-up, no results were
published about symptom or functioning levels.
The German Research Network on Schizophrenia
(GRNS): Early intervention in the Initial Prodromal
State (EIPS) (Germany). The GRNS study is
diﬀerent from the other three studies, because it
combines the UHR approach with the basic-
symptom approach, thus distinguishing two
diﬀerent putatively prodromal stage phases:
i) EIPS: presence of at least one basic symptom
of 10 basic symptoms that were found to have
a high sensitivity and positive predictive value
for developing schizophrenia in a 9.6-year
follow-up period (7) and ⁄or a state and trait
risk factor. The state and trait risk factor in
this study is a combination of a reduction in
Global Assessment of Functioning (GAF)
score of at least 30 points within the last
year and one of the following risk-factors:
ﬁrst-degree relative with diagnosis of schizo-
phrenia, a schizophrenia spectrum disorder in
the help-seeking person or pre- or perinatal
complications.
ii) Late Initial Prodromal State (LIPS): attenu-
ated psychotic symptoms (APS) and ⁄or
BLIPS.
The EIPS patients (n = 128) were randomized
to receive either a comprehensive CBT or support-
ive counselling (SC) for 12 months. The CBT was a
multimodal treatment programme comprising
individual CT, group intervention, cognitive reme-
diation and psychoeducational family intervention.
The LIPS patients (n = 124) were randomly
assigned to a needs-focused intervention (NFI) or
to NFI plus amisulpride.
For the LIPS group, only results on short-term
acute treatment eﬀects have been published, which
will be summarized below.
For the EIPS group, preliminary results
concerning prevention of psychosis have been
published without statistical analysis (3, 42).
Deﬁnitive results have only been described in
abstracts and presented at conferences (32, 33).
The risk of transition from EIPS to LIPS was
lower in the CBT group than in the SC group at
month 12 (3.2% vs. 16.9%, P = 0.008) and at
month 24 (6.3% vs. 20.0%, P = 0.019). The risk
of transition from EIPS to psychosis was also
lower in the CBT group than in the SC group at
month 12 (1.6% vs. 13.8%, P = 0.020). At month
24, no results of transition from EIPS to psychosis
have been published.
Medical University of Vienna: omega-3 fatty acids
(Austria). A research group of the Child &
Adolescent Psychiatry Unit of the Medical
University of Vienna, in cooperation with The
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Schlo¨ssli Clinic, O¨twil am See (Switzerland) and
ORYGENs Research Centre, Parkville (Austra-
lia), has chosen a diﬀerent intervention to evaluate.
They hypothesized that omega-3 fatty acids might
be eﬀective in preventing psychosis in UHR
individuals, based on earlier studies which impli-
cate that fatty acid deﬁciencies may contribute to
neurodevelopmental disorders (43).
They conducted a randomized, double-blind,
placebo-controlled trial testing the eﬀects of 1.5
g ⁄day omega-3 fatty acids in 81 adolescents (mean
age 16.4; range 13–24 years) with UHR symptoms
for developing psychosis. UHR state was deﬁned
by CAARMS criteria.
Supplementation was administered for 12 weeks;
follow-up was 12 months. The primary outcome
measure was transition to psychosis, operationally
deﬁned using PANSS criteria, and criteria for
frequency and duration of symptoms. Secondary
outcome measures were PANSS scores and GAF
scores.
Preliminary results have been described in two
abstracts and presented orally (34, 35):
i) Results at 12-week follow-up have been
described for 76 of the 81 adolescents. In the
omega-3 fatty acids group, one of 38 adoles-
cents (2.6%) made the transition to psychosis
in 12 weeks, compared with eight of 38 ado-
lescents (21.2%) in the placebo group. This
difference was signiﬁcant (P = 0.028). There
were also signiﬁcant diﬀerences at week 12 in
changes from baseline on PANSS scores
(positive symptoms and global symptoms)
and GAF score, in favour of the treatment
group. No side-eﬀects were observed.
ii) Results at 1-year follow-up were described for
the whole group. In the omega-3 fatty acids
group, two of 41 adolescents (4.9%) had made
the transition to psychosis, compared with 11
of 40 (27.5%) adolescents in the placebo
group. This difference was signiﬁcant
(P = 0.006).
OPUS trial, Copenhagen (Denmark). The OPUS
trial compared integrated treatment vs. standard
treatment in 547 patients who recently got a ICD-
10 diagnosis in the schizophrenia spectrum (schizo-
phrenia, acute or transient psychotic disorder,
schizoaﬀective disorder, other delusional disorders,
and schizotypal disorder) (44). The majority of
these patients had already experienced a ﬁrst
psychotic episode, a diagnosis beyond the scope
of this review. Seventy-nine patients, however,
received a diagnosis of schizotypal disorder and
never had a psychotic episode. This group has been
analysed separately (36). The criteria for schizo-
typal disorder in ICD-10 have some overlap with
UHR criteria (e.g. odd beliefs or magical thinking,
suspiciousness or paranoid ideas and unusual
perceptions are among the criteria for schizotypal
disorder and are items in the SOPS and the
CAARMS). Patients with a schizotypal disorder
are at a higher risk for developing a psychotic
episode, which makes this group interesting to
study for indicated prevention.
The integrated treatment in this trial consisted of
Assertive Community Treatment (ACT) with pro-
grammes for family involvement and social skills
training and lasted for 2 years. Medication pre-
scription was based on the decision of the psychi-
atrist of the individual patient in each treatment
condition.
The primary outcome measure was transition to
psychotic disorder, deﬁned as fulﬁlling the criteria of
an ICD-10 diagnosis of a psychotic disorder.
Secondary outcome measures were positive,
negative anddisorganized symptomson thePANSS.
In the integrated treatment group, 37 ⁄42
patients (88%) completed 1-year follow-up, and
36 ⁄42 (86%) patients 2-year follow-up. In the
standard treatment group, 30 ⁄37 patients (81%)
completed 1-year follow-up and 29 ⁄37 (78%)
patients the 2-year follow-up. Patients lost to
follow-up were excluded from analysis.
After 1 year, 3 ⁄37 (8.1%) patients were diag-
nosed with a psychotic disorder in the integrated
treatment group, compared with 10 ⁄30 (25.0%) in
the standard treatment group. After 2 years, the
number of patients diagnosed with a psychotic
disorder was 9 ⁄36 (25.0%) in the integrated
treatment group and 14 ⁄29 (48.3%) in the
standard treatment group. In a multivariate anal-
ysis, integrated treatment signiﬁcantly reduced the
risk of being diagnosed with a psychotic disorder
after 2 years (relative risk = 0.36, P = 0.02).
The level of positive and disorganized symptoms
was not diﬀerent between the two treatment
groups. The level of negative symptoms was
signiﬁcantly lower in the integrated treatment
group after 1 year, but not after 2 years.
Antipsychotic medication was prescribed to
many patients: 68% and 61% of the patients in 1-
and 2-year follow-up. As far as we know, no data
have been published about the proportion of
patients using antipsychotic medication in the
group that made transition to psychosis and in the
group that did not make transition to psychosis.
Trials without control intervention Szeged, Hungary:
haloperidol and risperidone. This Hungarian study
has been published in a Hungarian journal (45).
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Only the English translation of the abstract was
included in the present review.
A group of 52 UHR subjects (deﬁned with
PACE criteria) was treated for 6 months with
low-dose haloperidol or risperidone (0.5–
2 mg ⁄day), together with psychoeducation and
supportive psychotherapy, with a follow-up
period of 6 months. There was no control group.
Transition to psychosis was the primary outcome
measure. The operational deﬁnition of transition is
not mentioned in the abstract.
After 1 year, 42 ⁄52 (81%) patients completed
the study. Of these 42 patients, three patients
developed schizophrenia during the study (7.1%),
all three during the ﬁrst 6 months. Side-eﬀects were
mild and transient.
The authors conclude that low-dose haloperidol
or risperidone seems to be eﬀective in preventing or
postponing transition to psychosis, because the
transition rate is lower than the transition rate in
UHR subjects who do not get any treatment,
which is, according to the authors, 30–60%.
Naturalistic studies. Cornblatt and colleagues pres-
ent a diﬀerent vision on the subject (46–49). In 2001,
they pointed out that information was lacking on
several important topics in prodromal intervention
research. For example, in their opinion knowledge
was insuﬃcient to make a rational choice which
intervention to study, and to know how to measure
the eﬀectiveness.
They suggested that naturalistic studies were
necessary to provide this information. In 2007,
they conclude in a review that the situation is still
very much the same. They point out the disadvan-
tages of randomized controlled clinical trials for
prodromal intervention research:
i) Lack of generalizability.
ii) Medication non-adherence is a major problem
which often does not get enough attention in
clinical trials. It is a potential confounder.
iii) In a clinical trial, one treatment option has to
be chosen. Naturalistic studies are essential
because the range of potential treatments is
not limited. Results might show treatment
options with promising results that can be
evaluated in a randomized clinical trial after-
wards.
The Hillside Recognition and Prevention (RAP)
programme in New York is a clinical programme
with a naturalistic treatment strategy, for adoles-
cents (12–22 years) with UHR symptoms. A
diagnostic algorithm is used that makes use of
the SOPS, but with diﬀerent operationalization
criteria of the putatively prodromal state. The
authors use the term CHR for patients fulﬁlling
their inclusion criteria. They discerned two CHR
subgroups (48):
i) CHR) : patients that exhibited only attenu-
ated negative symptoms (this group is not
included in UHR criteria in CAARMS and
COPS, and is considered by the authors to
represent the earliest putatively prodromal
stage);
ii) CHR+: patients that exhibited attenuated
psychotic symptoms (APS, deﬁned as in
COPS).
The UHR categories BLIPS and state and trait
risk factor are no inclusion criteria in the RAP
programme.
From 1998 to 2005, 152 adolescents were
enrolled in the programme, of which 30 already
had a psychosis, but did not meet criteria for
schizophrenia. Of the remaining 122, 44 only had
attenuated negative symptoms (CHR)). Seventy-
eight adolescents had APS (CHR+).
From these 78 adolescents, 48 were selected for
analysis, with the following criteria: i) received
pharmacological treatment for at least 8 weeks and
ii) was followed up for at least 6 months (mean
30 months, maximum 60 months) (49).
Of these 48 adolescents, 20 never received
antipsychotics (APs), but received antidepressants
(ADs) alone or in combination with other medica-
tion (mainly mood stabilizers). Twenty-eight
adolescents received a second-generation AP,
often with an AD as co-medication.
During the follow-up of maximum 5 years, 12 of
the 28 adolescents who used an AP converted to
psychosis (43%), while none of the 20 adolescents
who used an AD without an AP converted. This
diﬀerence was statistically signiﬁcant. A logical
explanation of the high transition rate in the AP
group would be that the AP group was a more
severely ill group at baseline, being in a later phase
of the prodrome, which could have been the exact
reason they got prescribed an AP. However, the
baseline symptom proﬁles of the two groups did
not diﬀer except for disorganized thinking which
was more severe in the AP subgroup.
The high transition rate in the AP group could
also be due to a high percentage of non-adherence.
Seventeen of the 28 adolescents who used an AP
were non-adherent. Eleven of the 12 converters to
psychosis were non-adherent, thus only one adher-
ent AP-using adolescent converted to psychosis.
Non-adherence to APs was much higher than non-
adherence to ADs (61% vs. 20%, P = 0.005).
The authors conclude that ADs might be an
eﬀective treatment for UHR subjects, possibly
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because of the higher adherence to ADs than
to APs. They emphasize that the naturalistic
character of the study limits the comparisons
that can be made between the AD and AP
subgroup.
The results of Cornblatt et al. (49). prompted the
research group of Outreach And Support In South
London (OASIS), a clinical service for people with
UHR symptoms (deﬁned by the CAARMS) in
London, to do the same analysis in their group
(50). At the OASIS clinic, patients are invited to
make their own choice out of several interventions,
amongst others symptom monitoring, CBT,
antipsychotic medication and antidepressant med-
ication, after being informed about the possible
beneﬁts and risks (51).
They found similar results: during a follow-up of
2 years, 10 of 35 adolescents who used an AP
converted to psychosis (29%), while only one of
the 13 adolescents who used an AD converted
(8%) (50). No statistical analysis has been
published. As in Cornblatts group, the question
is whether the AP group was more severely ill at
baseline. Furthermore, intrinsic patient character-
istics may have inﬂuenced the outcome, because
the choice for an AP or an AD was based on the
patients preferences.
Acute treatment effects in UHR subjects
The UHR state is characterized not only by
symptoms and signs, but also by a decrease in
functioning in a vast majority of patients (52).
Therefore, some researchers focus on the syndrome
itself and the acute treatment eﬀects on symptoms
and functioning, independently from a possible
conversion to psychosis in the future. Furthermore,
in studies with short follow-up periods
(<6 months) this focus on symptom levels and
functioning is necessary, because of the often very
small number of transitions to psychosis after such
a short follow-up period. For example, in the four
studies described below the follow-up period is
12 weeks or less.
Olanzapine vs. placebo (PRIME study, USA). The
above-described double-blind, randomized,
placebo-controlled trial of olanzapine in UHR
subjects from McGlashan et al. (9) also generated
acute treatment results. Results of the ﬁrst 8 weeks
were analysed separately (53). Drop-out was high
in the ﬁrst 8 weeks (11 ⁄31 = 35% in the olanza-
pine subgroup, 8 ⁄29 = 28% in the placebo
subgroup).
The olanzapine group improved signiﬁcantly
more than the placebo group on diﬀerent symptom
scales. However, this was only the case when a
mixed eﬀect, repeated-measure analysis was used,
combined with post hoc analyses. In last observa-
tion carried forward analyses, which had been
planned on forehand, the scores at endpoint were
not signiﬁcantly diﬀerent, although there was a
trend of more improvement in the olanzapine
group. In the olanzapine subgroup, weight gain
was signiﬁcantly higher than in the placebo
subgroup.
Table 2. Studies on acute treatment effects in UHR subjects
Study Inclusion criteria
Specific intervention
(SI)
Control intervention
(CI) Primary outcome measure
Secondary outcome
measures
PRIME (53) UHR criteria (COPS)
(n = 60)
Olanzapine 5–15 mg
(n = 31)
8 weeks
Placebo (n = 29)
8 weeks
SOPS total score:
SI significantly more improvement than CI (but
dependent on which statistical method used)
Weight gain: % of
patients gaining more
than 7% of their
baseline body weight:
SI: 56.7%
CI: 3.4%
P < 0.001
GNRS LIPS
(54)
Attenuated positive
symptoms and ⁄ or
BLIPS (n = 124)
22 patients excluded
from analysis
Amisulpride 50–
800 mg + needs-fo-
cused intervention
(n = 58)
12 weeks
Needs-focused inter-
vention (n = 44)
12 weeks
Many scales:
Positive symptoms, negative symptoms, general
symptoms, depressive symptoms and GAF:
SI significantly more improvement than CI
Weight gain: BMI
increased slightly but
significantly in the SI
group, not in CI group
(difference signifi-
cant)
Woods et al.
(55)
UHR criteria (COPS)
(n = 15)
Aripiprazole 5-30 mg
(n = 15)
8 weeks
No SOPS total score:
Significant improvement from week 1
Side-effects:
Mean weight gain
1.2 kg
Acathisia in 8
patients
Woods et al.
(56)
UHR criteria (COPS)
(n = 10)
Glycine 0.4 g ⁄ kg
(n = 10)
8 weeks
No SOPS scores:
Significant improvement on SOPS total scores
and on all subscales except negative symptoms
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Amisulpride vs. a needs-focused intervention (GRNS:
LIPS trial, Germany). The GRNS study has been
described above. The patients in the LIPS
(n = 124) were randomly assigned to an NFI
(n = 59) or to NFI plus amisulpride, in a dose
range from 50 to 800 mg (n = 65) (54). The study
was open-labelled.
Of the 124 patients, 102 were considered for
analysis. In the amisulpride group, seven patients
were excluded from analysis: three because
treatment had already started before baseline
assessment (protocol violation) and four because
they did not return after randomization.
In the NFI alone group, 15 patients were
excluded from analysis: 10 because they did not
return after randomization, one because of a
serious somatic problem and four because at the
baseline assessment they proved to be psychotic
and ⁄or used antipsychotic medication.
It is questionable if all these exclusions do not
violate the intention to treat principle. In the
remaining sample, drop-out was 15 ⁄58 (26%) in
the amisulpride group and 15 ⁄44 (34%) in the NFI
alone group. At week 12, scores on diﬀerent
symptom and functioning scales were reported, as
well as side-eﬀects.
Symptoms and functioning ameliorated in both
groups during these 12 weeks. The NFI plus
amisulpride group ameliorated signiﬁcantly more
than the NFI alone group on all measures.
The body mass index (BMI) increased signiﬁ-
cantly in the amisulpride group and not in the NFI
alone group. Other side-eﬀects were mainly
associated with increased prolactin levels, like
diminished sexual desire.
Aripiprazole: an open-labelled pilot study. Woods
et al. (55) included 15 UHR participants with a
mean age of 17.1 years. UHR state was operation-
alized by COPS criteria. The participants were
enrolled in an open-labelled trial with aripiprazole
treatment for 8 weeks, without control interven-
tion. Aripiprazole dosing varied between 5 and
30 mg ⁄day. During these 8 weeks, two participants
dropped-out (13%).
The principal outcome measure was the severity
of prodromal symptoms (SOPS total score).
Improvement from baseline was statistically
signiﬁcant, with a mixed eﬀect, repeated-measure
analysis. No participant converted to psychosis
during these 8 weeks. Mean weight gain was
1.2 kg. Acathisia emerged in eight participants.
The authors conclude that aripiprazole is possi-
bly eﬀective and relatively safe for UHR subjects,
but they emphasize that placebo-controlled studies
are needed.
Glycine: an open-labelled pilot study. Woods et al.
(56) included 10 UHR patients with a mean age of
17.3 years. The UHR state was deﬁned by COPS
criteria. The participants were enrolled in an open-
labelled trial with glycine 0.4 g ⁄kg for 8 weeks,
with follow-up of 16 more weeks, without control
intervention. Glycine is an amino acid neurotrans-
mitter that acts as a coagonist with glutamate at
N-methyl D-aspartate (NMDA) receptors. It is no
standard treatment for psychosis. It is hypothe-
sized that NMDA hypofunction is associated with
developing schizophrenia, which makes glycine an
interesting potential treatment (56).
Outcome measures were changes on SOPS total
scores, and positive, negative, disorganization and
general symptom subscales.
To our knowledge, the results were only
described in an abstract. During the 8 weeks of
treatment, 3 ⁄10 patients dropped-out (one because
of lack of eﬃcacy and two because of transporta-
tion or family diﬃculties). Patients improved
signiﬁcantly from baseline on the SOPS total
score (P < 0.001) and on all subscales except the
negative symptom subscale.
The authors conclude that the NMDA-agonist
glycine might be eﬀective in prodromal patients
and that placebo-controlled trials are necessary.
Discussion
The main conclusion of this review was that we
are unable to draw a ﬁnal conclusion about the
eﬃcacy and safety of interventions for UHR
subjects.
Summary of the results
Prevention of transition to psychosis. In the PACE
study, CBT + risperidone signiﬁcantly lowered the
transition rate to psychosis compared with the NBI
group at the end of the 6-month treatment phase,
but during the follow-period of 1–4 years this eﬀect
was no longer present (23, 30). This might suggest
that the intervention is eﬀective in delaying
psychosis for months; that might be an indication
for continuation of the intervention. The separate
contribution of risperidone and CBT is not known.
Neuroleptic adverse eﬀects were present in four
patients.
In the PRIME study, no signiﬁcant eﬀects were
found of olanzapine compared with placebo on
the transition rate to psychosis (9). Conversely,
signiﬁcantly higher adverse eﬀects were reported in
the olanzapine group (weight gain and fatigue
mainly). Drop-out was high, especially in the
olanzapine group. The study may have been
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underpowered, because the transition rate seemed
much lower in the olanzapine group, especially at
the end of the treatment year.
In the EDIE study, 6 months of CT signiﬁcantly
lowered the transition rate to psychosis compared
with the monitoring group after 1 year (29).
However, a methodological discussion about the
exclusion of two patients complicates this ﬁnding.
At 3-year follow-up, the transition rate in the CT
group was still signiﬁcantly lower, but only when
transition was deﬁned as being prescribed antipsy-
chotic medication, which was only one of the three
operationalizations of the primary outcome
measure (31).
Results of the GRNS trial have only been
described in abstracts (32, 33). The absolute
numbers and information about drop-out and
other methodological issues have not yet been
published, so no deﬁnitive conclusions can be
drawn. Data thus far suggest that 12 months of
this specially developed comprehensive CBT are
eﬀective in lowering transition from EIPS to LIPS
and from EIPS to psychosis.
One study on the possible therapeutic eﬀects of
12 weeks of omega-3 fatty acids was described in
two abstracts (34, 35). Supplementation of omega-
3 fatty acids for 12 weeks signiﬁcantly lowered the
transition to psychosis at week 12 and at 1-year
follow-up. No side-eﬀects were observed. These
ﬁndings suggest that omega-3 fatty acids could be
eﬀective and safe in preventing psychosis in UHR
subjects, possibly with a lasting eﬀect after supple-
mentation of only 12 weeks. As results have only
been presented in abstracts so far, methodological
issues will have to be evaluated after publication of
a full article.
One study on the eﬃcacy of integrated treat-
ment (ACT with family intervention and social
skills training) compared with standard treatment
in patients with schizotypal disorder showed a
signiﬁcantly lower relative risk of transition to
psychosis in the integrated treatment group (36).
An important limitation of the study is the
exclusion of dropped-out patients from statistical
analysis. It is not clear if the signiﬁcant eﬀect
would have been found with an intention to treat
analysis. Another limitation is the prescription of
antipsychotic medication to many patients, which
can be a confounding factor. However, results of
the intervention are promising. Although the
patient group is diﬀerent from patients fulﬁlling
UHR criteria, the intervention could be of great
importance for UHR patients also. Because of the
study design, it is not possible to conclude what
elements from the integrated treatment were the
eﬀective ones.
The last study on transition to psychosis found
a transition of 7.1% in UHR subjects treated with
low-dose haloperidol or risperidone for 6 months
(45). There was no control group. Although this
transition rate is lower than in many studies
without a speciﬁc treatment, the variation in
transition rates in naturalistic studies is high
(15), and one cannot be sure that the studied
subjects are comparable with subjects in earlier
research groups with no treatment. A control
group is necessary to be able to interpret the
results.
Two naturalistic studies show a possible eﬀect of
ADs in patients with UHR symptoms, lowering the
transition rate to psychosis (49, 50). It is possible
that a low mood plays a causal role in the
development of a psychosis because it leads to a
more paranoid interpretation of beginning
anomalous experiences (57). The major question
is the possibility that the patients who were
prescribed ADs were a subgroup with a better
prognosis than the patients who were prescribed
APs. In Fusar-Polis group, the outcome may also
have been inﬂuenced by intrinsic patient charac-
teristics, because the choice for an AP or an AD
was based on the patients preferences (51). Ran-
domized trials are necessary to test the possible
therapeutic eﬀect of ADs and to evaluate drug
safety and tolerability (50).
Acute treatment eﬀects. Summarizing four studies
on acute treatment eﬀects, we conclude that a
signiﬁcant symptomatic improvement was found
for olanzapine and for amisulpride compared with
a control intervention (53, 54). However, method-
ological issues complicate the ﬁndings: in the ﬁrst
study diﬀerent statistical methods are used, and in
the second study 22 patients are excluded from
analysis on forehand for diﬀerent reasons.
The third and the fourth study are studies
without a control intervention, which makes
conclusions about the eﬀect of the medication
(aripiprazol and the NMDA-agonist glycine
respectively) impossible (55, 56).
In these four studies, drop-out varied from 13 to
35% in 8–12 weeks. Weight gain and acathisia
were the main side-eﬀects of the APs.
In conclusion, all treatment studies with
antipsychotic medication and ⁄or CT ⁄CBT and ⁄or
family intervention and ⁄or social skills training,
suggest a positive eﬀect of the intervention at the
end of treatment. Omega-3 fatty acids give prom-
ising results, but publication of a full article has to
be awaited to evaluate methodological issues.
For ADs and glycine, no conclusions can be
drawn. The positive eﬀect of antipsychotic
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medication and CT ⁄CBT seems to have disap-
peared at follow-up.
A methodological problem when comparing the
diﬀerent studies is the operational deﬁnition of
the UHR state and of transition to psychosis.
Diﬀerent instruments have been used for this
purpose.
Potential benefits of antipsychotic medication and CT ⁄ CBT as
prepsychotic interventions
The results suggest that, if there is a therapeutic
eﬀect, it seems to be delay of onset of psychosis,
and not prevention, because the possible therapeutic
eﬀects disappear after the end of the intervention
period. Hypotheses about improving clinical out-
come after the ﬁrst psychosis by delaying its onset
have not been proven.
Furthermore, in all follow-up studies the func-
tioning of the UHR subjects remained poor, even if
they did not convert to psychosis. UHR symptoms
seem to indicate a serious mental health problem.
This might mean that treatment (e.g. antipsychotic
medication or CBT) is necessary and should not be
stopped after a certain period. However, until now,
no studies with treatment periods longer than
2 years have been published.
Potential risks of antipsychotic medication and CT ⁄ CBT as
prepsychotic interventions
The known side-eﬀects of second-generation anti-
psychotic medication are clearly present in UHR
subjects, as are adherence problems (49). Extrapy-
ramidal symptoms, weight gain and metabolic
complications are major issues nowadays in the
treatment of psychotic patients. When used as
prepsychotic intervention, with no proven long-
term eﬀects, the beneﬁt ⁄ risk ratio is even more
unfavourable. Furthermore, antipsychotic medication
may lead to upregulation of D2 receptors, which
might raise the chance of transition to psychosis
after stopping the medication.
These risks do not hold for CT ⁄CBT, but the
potential risk of stigmatizing or anxiety induction
when using the word psychosis does. However, in
all studies the education about psychosis and about
the uncertainty of transition seems to be very well
accepted. Furthermore, Fusar-Poli et al. (50)
found in their service that CBT is more easily
accepted by their UHR subjects than any type of
medication.
Finally, when intervening in the UHR state, the
question when the intervention should stop, is very
complex, and has not yet been answered. False
false positives cannot be discerned from false
positives, so when a subject with UHR symptoms
does not progress to psychosis, one does not know
if that was because of the intervention or not. But
even if it would be sure that a subject has not
progressed to psychosis because of the interven-
tion, it is not known for how long the intervention
has to be continued. Prescribing an intervention
for many years without knowing the answers to
these questions is not ethical, especially when
side-eﬀects can be serious, as is the case for
antipsychotic medication.
Future developments: better prediction?
The transition of UHR symptoms and signs to a
psychotic disorder is obviously uncertain, so the
problem of false positives remains. Cannon and
colleagues (41) have demonstrated that prediction
algorithms can be improved, resulting in a positive
predictive power (PPP) of 68–80%, which is much
higher than the PPP of the criteria used until now.
This improvement of PPP resulted from adding
certain features to the prediction model, e.g.
greater social impairment, history of substance
abuse, higher levels of suspicion ⁄paranoia. If this
ﬁnding of an increased PPP is replicated, the eﬀect
of interventions might increase as well, and the
beneﬁts and risks ratio might be more favourable.
However, Yung (58) comments on Cannons
results, noting that the sensitivity may be reduced
when the PPP is increased by adding certain
selection criteria. It depends on the aim of the
study if sensitivity should be sacriﬁced to minimize
false positives.
Even with better prediction algorithms, the
emphasis of the selection criteria will be on
attenuated psychotic symptoms and brief limited
psychosis, simply because they are the most speciﬁc
putatively prodromal symptoms for psychosis. In
the case of schizophrenia, these symptoms are
probably not core risk factors, but the more
dramatic manifestations of the disease. The core
features of schizophrenia are probably neurocog-
nitive dysfunctions and negative symptoms, which
are far more diﬃcult to inﬂuence (47). Therefore,
delaying or even preventing transition to psychosis
can be important, but may not be correlated with a
long-term better clinical outcome. An interesting
study would be the comparison between the
outcomes of treated prodromal subjects who
converted to psychosis and patients with a ﬁrst
psychotic episode who never received treatment
during the prodromal phase, as suggested by
Phillips et al. (30).
Furthermore, it is important to realise that, even
with highly available early intervention services,
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there will always be patients who present with a
ﬁrst psychotic episode without having sought help
during the prodromal phase.
Implications for clinical practice
Antipsychotic medication as prepsychotic inter-
vention might delay the onset of psychosis, and
might have therapeutic eﬀects on the prepsychotic
symptoms, but this has not yet been proven. On the
other hand, serious side-eﬀects and adherence
problems are present, as is the risk that antipsy-
chotic medication leads to upregulation of D2
receptors and raises the chance of transition to
psychosis after stopping the medication. We
conclude that the results are promising enough to
justify further research, but that antipsychotic
medication should be no standard clinical practice
in the UHR state.
The therapeutic eﬀect of CT ⁄CBT and family
intervention has not been proven either, but we
think these are more suitable options, because
side-eﬀects have not been demonstrated. Antide-
pressive medication and omega-3 fatty acids might
be promising alternatives, but further research is
necessary.
As there is no conclusive evidence for one type of
intervention, a possible strategy when treating an
UHR subject is providing extensive information
about the possible beneﬁt and risks of social
support, symptom monitoring, CBT, antidepres-
sant and antipsychotic medication, family
intervention, psychoeducation, and social skills
training, and providing treatment based on the
patients preferences. The patient might choose
only to receive social support and monitoring, but
might also ask for CBT or even antipsychotic
medication. For example, the OASIS clinic in
London is following this strategy (51).
International clinical practice guidelines for
early psychosis have been published in 2005 (59).
An update will probably be published in 2009.
Given the available research at present, these
guidelines still seem to be valid. The most impor-
tant advices in the guidelines for UHR subjects are
(modiﬁed from) (59):
i) regular monitoring of mental state and offer
support;
ii) speciﬁc treatment for syndromes, such as
depression, anxiety or substance misuse, and
assistance with problem areas such as
interpersonal, vocational and family stress if
present;
iii) psychoeducation;
iv) family education and support;
v) provide information in a ﬂexible, careful and
clear way about risks for mental disorders as
well as about existing syndromes;
vi) antipsychotic medication is not usually indi-
cated. Exceptions should be considered when
rapid deterioration is occurring;
vii) the evidence of effectiveness of treatments
aimed speciﬁcally at reducing the risk of
transition psychosis (e.g. cognitive and family
therapy, antipsychotic medication or experi-
mental neuroprotective drug strategies)
remains preliminary. More data are required
and the risk ⁄beneﬁt ratio of various interven-
tions needs to be determined.
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